OncoSil Decision Shows How FDA's Humanitarian Device Exemption Works

OncoSil Medical's device for a rare bile duct cancer has reached the US market through the FDA's Humanitarian Device Exemption program. The agency's HDE database entry, H200002, lists a decision date of Aug. 14, 2026, for an application received on Aug. 5, 2020. The company announced the decision on Aug. 17, CancerNetwork reported.

According to the FDA record, OncoSil is intended for implantation into a solid tumor by injection under endoscopic ultrasound guidance, and is indicated for patients over 21 with distal cholangiocarcinoma that is both unresectable and non-metastatic, as an adjunct to systemic therapy. CancerNetwork described it as delivering phosphorus-32 microparticles into the tumor. The record also links a "Summary of Safety And Probable Benefit." The phrase "probable benefit" marks the main difference between this pathway and ordinary premarket approval.

A pathway for small populations

FDA's HDE program page explains the problem it was built to solve: because rare conditions occur in few patients, "it has been difficult to gather enough clinical evidence to meet the FDA standard of reasonable assurance of safety and effectiveness." Congress responded in the Safe Medical Devices Act of 1990.

The program has two steps. First, a device is designated a humanitarian use device, or HUD, which FDA defines as a device intended to benefit patients with a disease or condition that "affects or is manifested in not more than 8,000 individuals in the United States per year." Under the regulations at 21 CFR Part 814, Subpart H, the company asks FDA's Office of Orphan Products Development for that designation before it applies. Second, the company files the HDE itself, a marketing application that FDA says "is exempt from the effectiveness requirements" of the law's premarket approval sections.

In place of proof of effectiveness, the regulations require the application to explain "why the probable benefit to health from the use of the device outweighs the risk of injury or illness from its use," taking into account the risks and benefits of other available treatments. The company must also explain why the device would not be available without an HDE and state that no comparable device is available.

Limits that come with the exemption

An HDE carries conditions that a standard approval does not. The regulations make the HDE holder responsible for ensuring the device is used only in facilities overseen by an institutional review board, and say a humanitarian use device "may be administered only if such use has been approved by an IRB," with an exception for emergencies.

Profit is also restricted. FDA says a humanitarian use device may be sold for profit only if it is meant for a pediatric condition, or for an adult condition that does not occur in children or occurs in too few children for device development to be practical. Even then, profitable sales are capped at an annual distribution number, calculated by multiplying the number of devices reasonably needed per patient per year by 8,000. Above that number, the company can keep selling but cannot earn a profit for the rest of the year.

What OncoSil's rollout looks like

CancerNetwork reported that, under the terms of the HDE, the US rollout will initially be limited to at most five treatment centers with trained practitioners, as part of an FDA-required post-approval study that will evaluate safety and probable benefit in up to 30 patients over 24 months. The FDA record links a post-approval study schedule. According to the company's release, as reported by CancerNetwork, it is the only FDA-approved Class III device for treating distal cholangiocarcinoma.